Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rep. DeLauro on conflicts

This article was originally published in The Gray Sheet

Executive Summary

FDA should consult the National Institutes of Health on how to find "fully qualified professional advisors who give the agency the best unbiased advice possible...free of conflict or any appearance thereof," Congresswoman Rosa DeLauro (D-Conn.) said Feb. 16 during a hearing on FY 2007 appropriations. Last year's FDA appropriations bill included an amendment requiring public disclosure of panel member conflicts of interest. Since its passage on Oct. 28, 2005, FDA has allowed 55 conflict-of-interest waivers - "a heck of a lot of waivers," DeLauro opined. She suggested that full disclosure of advisory committee conflicts of interest is still not a reality...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel